Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...
Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...
This review focuses on patient care tips and practices for the care of patients with B-NHL or MM receiving bispecific antibody therapy.
A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results